BIDS

Bronchiolitis is a self limiting viral lung infection of infants. The number of admissions to hospital has doubled in the past 25 years, possibly because oxygen (saturation) monitors now detect borderline low oxygen levels not previously identifiable clinically. Two recent guidelines differed in what experts considered the correct oxygen saturation level in air to stop therapeutic oxygen (there is no evidence): one recommended 90% the other 94%. This difference could represent 22 hours longer in hospital.

The BIDS study evaluated the clinical and cost effects of accepting 90% rather than 94% oxygen saturation as the upper limit for providing therapeutic oxygen. As at present, infants will only go home when clinicians consider they are ready (comfortable breathing and feeding adequately). 

• link: BIDS study protocol
• link: BIDS study statistical analysis plan

Image

Chief Investigator: Dr Steve Cunningham

Number and location of participating sites (by region/ country: 5 sites in Scotland (Aberdeen, Dundee, Edinburgh, Glasgow, Kilmarnock).  3 sites in England (Bristol, Exeter, Truro).

ISRCTN number: ISRCTN28405428  http://www.controlled-trials.com/ISRCTN28405428/BIDS

Funder: NIHR HTA programme

Start and End date of grant award: started 01 Jul 2011 and ended 28 Feb 2014

Image

Congratulations!

The BIDS Lancet paper has won an award.  It is the BMJ Clinical Research Paper of the Year 2016 .

Judges Comments:  With this study, defining oxygen saturation targets in infants with bronchiolitis can finally move from opinion based to evidence based medicine.  The study is elegantly designed and brings robust evidence to treatment decisions concerning one of the most common causes of hospital admissions in infants.

Dr Steve Cunningham:  The findings mean that fewer patients will require supplemental oxygen.

Current Status: Complete and published.

http://www.journalslibrary.nihr.ac.uk/hta/volume-19/issue-71#abstract

http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)00163-4/abstract

Trial Unblinding Information: In circumstances where unblinding is necessary please refer to the protocol and follow instructions provided. Contact details are provided below.

UK GDPR Privacy Statement: If you have participated in this study and would like to read how it complies with UK GDPR, please read this document.

Contact details:      Dr Steve Cunningham (Chief Investigator).

Morag MacLean (Trial Manager) tel: 0131 537 3846; morag.maclean@ed.ac.uk 

ECTU Involvement: Trial management / Statistics / Data base / randomisation service provision